Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).
The purpose of this study is to evaluate the level of satisfaction experienced by asthma or chronic obstructive pulmonary disease (COPD) patients when using the Fluticasone/Salmeterol HFA Metered Dose Inhaler (MDI) with counter, as compared to using Fluticasone/Salmeterol HFA MDI without counter.
Official Title
An Open Label, Multicentre Study to Evaluate Patient Satisfaction With Fluticasone/Salmeterol HFA MDI With Counter in Adult Subjects (18 Years of Age and Older) With Asthma or COPD.
Conditions
Asthma, COPD (Chronic Obstructive Pulmonary Disease)
Study Type
Interventional
Study Design
Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study
Further Details
Primary Outcome Measures:
- Patient satisfaction questionnaires administered at baseline and at the end of treatment (day 30).
Secondary Outcome Measures:
- Healthcare professional satisfaction questionnaires administered at baseline and at the end of treatment (day 30)
- Patient compliance as measured by the device counter readings at the end of treatment (day 30), compared to the baseline reading.
Study Start
December 2006
Eligibility & Criteria
- Ages Eligible for Study: 18 Years and above
- Genders Eligible for Study: Both
Inclusion Criteria:
- Outpatient
- Documented physician diagnosis of asthma or COPD
- Requires use of a controller and long acting beta 2 agonist
- Ability to provided written informed consent
Exclusion Criteria:
- Patients with life threatening asthma or COPD
- Historical or current evidence of significant diseases
- Immediate or delayed hypersensitivity to inhaled short acting beta2agonist or sympathomimetic drug or any component of the MDI formulation
- History of drug or alcohol abuse Abnormal chest x ray not consistent with asthma or COPD
- Use of supplemental oxygen; systemic corticosteroids; short acting beta2agonists other than VENTOLIN HFA; antibiotics for respiratory infections; anti-arrhythmics; anticonvulsants; central nervous system stimulants; tricyclic antidepressants and monoamine oxidase inhibitors.
Total Enrolment
150
Contact Details
- Newcastle, New South Wales, 23120, Australia; Terminated
- Kippa Ring, Queensland, 4021, Australia; Not yet recruiting (as of March 2007)
- Perth, Western Australia, 6000, Australia; Recruiting
Contact GlaxoSmithKline Australia for more information (Please refer to this study by ClinicalTrials.gov identifier: NCT00404261)
Dates
Tags
Created by: